Sopan Pharmaceuticals Limited is set to open its Initial Public Offering (IPO) to the general public from Baisakh 2, 2083, marking a key step in the company’s capital market entry.

The company plans to issue a total of 3,474,900 units of ordinary shares. The subscription window will remain open until Baisakh 6, providing investors a limited timeframe to participate in the offering.

Investors will be able to apply for a minimum of 10 units and a maximum of 11,000 units, in line with regulatory provisions governing public share issuance in Nepal.

NMB Capital Limited has been appointed as the issue and sales manager for the IPO, overseeing the distribution and application process.

The public offering is expected to strengthen the company’s capital base while offering investors exposure to Nepal’s growing pharmaceutical sector. Market participants will closely monitor subscription levels and investor response, particularly amid increasing interest in sector diversification within the equity market.